Membranes were then washed 3 × with PBS-T

and incubated for 1 h at RT with rabbit anti-mouse HRP conjugated Epigenetic signaling pathway inhibitor secondary antibody 1:2000 in PBS-T (Abcam, ab6728), before visualization with enhanced chemiluminescence (ECL,Thermo Scientific, 32209) in a dark room. Comparisons were made between control plates of cells and differences at the 5% level considered significant. Multiple-time accumulation data were analysed by Two Way Repeated Measures ANOVA tests and Holm–Sidak posthoc tests, MTT assay data were compared against controls using a One Way ANOVA using Sigma Plot version 11.0 software (SPSS Science Software UK Ltd., Birmingham UK). All data are expressed as mean ± SEM, except MTT data which are expressed as percentage viability. The authors acknowledge that there are no conflicts of interest. The authors would like to thank Olaparib research buy Professor Pierre Couraud and Dr Ignacio Romero for the hCMEC/D3 cell line and Mr Enrico Cristante (Imperial College London) for the HepG2 cell line. We would also like to thank Dr Jonathan

Corcoran and Dr Maria de Castro Vasconcelos Goncalves (King’s College London) for their help with the confocal microscopy. This work was supported by the Wellcome Trust [080268] and an EPSRC DT grant (EP503523/1). “
“The blood–brain barrier is formed by brain endothelial cells lining cerebral microvessels, and performs a combination of physical, transport and enzymatic barrier functions (Abbott et al., 2010). The physical barrier is largely the result of extremely tight zonulae occludentes (tight junctions), which seriously restrict the paracellular flux of small hydrophilic molecules ( Tsukita et al., 2001 and Wolburg and Lippoldt, 2002). The transport barrier results from a combination of specific membrane carrier systems for uptake and efflux

Paclitaxel in vitro that regulate small molecular traffic at apical (luminal) and basal (abluminal) membranes ( Begley, 2004, Hawkins et al., 2002 and Hawkins et al., 2006), together with receptor-mediated and absorptive-mediated transcytosis (RMT, AMT) that mediate the transfer of small amounts of larger molecules such as peptides and proteins ( Hervé et al., 2008 and Wolburg et al., 2009). The enzymatic barrier results from the presence on and within brain endothelial, of ecto- and endo-enzymes capable of metabolising endogenous and exogenous compounds ( Abbott et al., 2006 and Persidsky et al., 2006). The net result of all three barrier functions is protection of the brain from potentially toxic or neuroactive agents capable of disturbing neural function, and a contribution to homoeostatic regulation of the brain microenvironment that is essential for neural activity and integration. Increased understanding of BBB function has come from careful study in vivo, traditionally using animal models, and increasingly involving minimally invasive investigation, where the technologies allow, in human subjects ( Hawkins and Egleton, 2007 and Rebeles et al., 2006).